Wedbush Upgrades Y-mAbs Therapeutics (NASDAQ:YMAB) to Outperform

Wedbush upgraded shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Get Rating) from a neutral rating to an outperform rating in a report published on Wednesday morning, MarketBeat reports. They currently have $13.00 price objective on the stock, up from their prior price objective of $5.00. Wedbush also issued estimates for Y-mAbs Therapeutics’ Q2 2023 earnings at […]

Related Keywords

New York ,United States ,America , ,Renaissance Technologies ,Prudential Financial Inc ,Nasdaq ,Canaccord Genuity Group ,Morgan Stanley ,Rice Hall James Associates ,America Corp ,Y Mabs Therapeutics Inc ,Y Mabs Therapeutics ,Get Rating ,Genuity Group ,Abs Therapeutics Trading Down ,Abs Therapeutics ,Rice Hall James ,Hall James ,Thomas Gad ,Y Mabs Therapeutics Daily ,Nasdaq Ymab ,Kymab ,Medical ,Upgrade ,Wedbush ,